2023년 세계 ISH(In Situ Hybridization) 시장 규모는 16억 4,000만 달러에 달했습니다. 이 시장은 2031년에는 35억 3,000만 달러에 달할 것으로 예상되며, 2024년부터 2031년까지 예측 기간 동안 10.04%의 CAGR을 기록할 것으로 예상됩니다. 세계 ISH(In Situ Hybridization) 시장은 매우 역동적이고 유망하며, 견고한 제품과 유리한 시장 전술을 가지고 있습니다. ISH(In Situ Hybridization) 시장은 암 환자 및 유전성 질환의 유병률 증가, 연구 및 개발에서 ISH(In Situ Hybridization) 기술의 사용 사례의 증가, 분자생물학 및 유전체학의 발전 등의 요인에 의해 주도될 것으로 예상됩니다.
암과 같은 질병의 진단 및 관리에서 ISH(In Situ Hybridization) 기술의 효능이 입증되면서 의료 전문가들의 채택이 확대되고 있습니다. 최근 몇 년 동안 여러 연구 기관에서 ISH(In Situ Hybridization)의 잠재력을 탐구하기 위해 대규모 연구를 수행했습니다. 이는 연구 개발 시나리오를 강화하고 이러한 제품에 대한 수요를 크게 증가시켰습니다. 따라서 전 세계적으로 암 환자의 증가는 ISH(In Situ Hybridization) 기술이 암세포와 유전자 변이를 감지하는 데 매우 효율적이기 때문에 수요를 촉진하는 주요 요인으로 작용하고 있습니다. 그러나 제품과 관련된 높은 비용, 숙련된 전문가 부족, 복잡한 데이터 해석은 세계 ISH(In Situ Hybridization) 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
이 보고서는 세계 ISH(In Situ Hybridization) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 기술별, 프로브 유형별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등의 정보를 제공합니다.
Global in situ hybridization market size was valued at USD 1.64 billion in 2023 and is expected to reach USD 3.53 billion in 2031, with a CAGR of 10.04% for the forecast period between 2024 and 2031F. The global in situ hybridization market is highly dynamic and promising, with a robust product and favorable market tactics. The in-situ hybridization market is expected to be driven by factors such as the increasing prevalence of cancer cases and genetic disorders, the growing use of in-situ hybridization techniques in research and development, and advancements in molecular biology and genomics.
The proven efficacy of in situ hybridization techniques in diagnosing and managing diseases like cancer led to their growing adoption by healthcare professionals. Several research organizations have spent the last few years conducting extensive research to explore possibilities around in situ hybridization. It has enhanced the research and development scenario and led to significant growth in demand for such products. Hence, growing cancer cases across the globe is a major factor driving the demand for in situ hybridization techniques as it is highly efficient in detecting cancerous cells and genetic mutations. However, the high cost associated with products, lack of highly skilled professionals, and interpretation of complicated data are some hindrances in the growth of the global in situ hybridization market.
In May 2023, Bio-Techne announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope in situ hybridization (ISH) portfolio with the commercialization of RNAscope multi-omic workflow for the Standard BioTools Hyperion Imaging System.
Bio-Techne is an international life sciences firm providing innovative tools and bioactive reagents for research and clinical diagnostics. The RNAscope is considered the gold standard for in situ hybridization and is trusted by biotechnological researchers worldwide, with a rapidly growing list of over 8,000 peer-reviewed publications.
In situ hybridization techniques are used in genetic testing for cancers. These techniques help to detect chromosomal changes in patients and help healthcare professionals to identify the type of cancer, based on which the treatment is designed. Due to vast applications of in situ hybridization, techniques in the diagnosis of cancers and other genetic diseases are further driving the demand in the market. Besides cancers, in situ hybridization techniques are extensively utilized to diagnose other indications like infectious, viral, and immunological diseases. The American Society of Cancer estimates that 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Cancer Research UK estimates that there will be 28 million cancer cases per year by 2040. It states that the United Kingdom's incidence is ranked higher than 90% of the world.
The global in situ hybridization market is positively impacted by increased research and development surrounding genome exploration, diagnostic research, and its other healthcare and life sciences applications. Over the past few decades, the human genome project has significantly contributed to the growing body of research concerning genetic explorations and life sciences research. The market is anticipated to rise significantly with the growing acceptance and application of in situ hybridization in diagnostic centers, hospitals, and institutional and academic research projects. To increase their worldwide presence, major companies in the market are pursuing tactics including new launches, mergers and acquisitions, and partnerships.
In February 2023, Molecular Instruments (MI), which is a biotech firm under the umbrella of the California Institute of Technology, launched HCR RNA-CISH. The product is expected to stimulate automated chromogenic in situ hybridization (ISH) workflows that depend on Bio-Techne's RNAscope. According to the company, HCR RNA-CISH kits offer twice the turnaround time and half the cost of any current chromogenic in situ hybridization (CISH) method, while delivering superior performance. HCR RNA-CISH has native support for IHC codetection and is fully compatible with all popular automation platforms.
The fluorescent in situ hybridization (FISH) technique finds a vast range of usage in the diagnosis of congenital disorders like Down's syndrome and other genetic diseases including cancer detection and identification. The growing application areas of fluorescent in situ hybridization (FISH) and its growing demand due to the rising burden of cancers and other genetic diseases is expected to make the fluorescent in situ hybridization (FISH) segment dominate the in situ hybridization market. The COVID-19 pandemic significantly boosted in situ hybridization and several research was done on it. For instance, in September 2023, a group of researchers published a protocol in STAR protocol, for the detection of infectious SARS-CoV-2 virus at low levels through in situ hybridization techniques.
North America is anticipated to dominate the market with the highest value share regarding its significant investment in research and development, technical breakthroughs made by major companies, highly developed healthcare infrastructure, and well-established research environment in North American nations like the United States and Canada. The government's actions and initiatives to assist medication development, genetic exploration, and cancer treatment contribute to the market's growth.
Market players are expanding their product offerings and giving their customers access to a wide range of cutting-edge and novel products using a variety of tactics. Companies are expanding the range of products they offer to gain market share. Industry participants are using a variety of growth methods, including collaborations, mergers and acquisitions, partnerships, product launches, and development of new solutions, to bolster their position in the market.
In October 2023, Ikonisys SA partnered with Biocare Medical to expand the FISH diagnostic product portfolio. Biocare Medical is a leading firm providing immunohistochemistry (IHC) and Fluorescent in situ hybridization (FISH) tools and reagents while Ikonisys SA specializes in early and accurate detection of cancer through its unique fully automated solution for medical diagnostic labs. This partnership focuses on expanding the global distribution of products of Ikonisys SA, especially, the low-volume Ikoniscope20 and high-volume Ikoniscope20max. Earlier, Biocare Medical acquired Empire Genomics to expand its offering to include over 1 million FISH probes.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.